Key result
A review of clinical trial design in progressive multiple sclerosis highlights the need for better participant selection, phase 2 biomarkers, improved clinical measures, and innovative trial paradigms.
Population
Patients with progressive multiple sclerosis
Design
Review
Authors
Loading...
Trial designs for progressive MS need refinement; leaves open which biomarkers and paradigms will best advance therapies.
Highlights the need for innovative trial designs, better biomarkers, and improved clinical measures to advance therapies for progressive multiple sclerosis.
Fox et al. (2017) conducted a review in Progressive multiple sclerosis. A review of clinical trial design in progressive multiple sclerosis highlights the need for better participant selection, phase 2 biomarkers, improved clinical measures, and innovative trial paradigms.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: